ARAY.NASDAQAccuray INC

Form 4: Accuray CCO Reports Stock Transactions, RSU Grant

Sentiment:

Insider Transaction Report


Accuray's Chief Commercial Officer, Sandeep Chalke, reported significant stock transactions including RSU grants, exercises, and tax-related dispositions.

Summary

  • Sandeep Chalke, SVP, Chief Commercial Officer of Accuray Inc. (ARAY), reported multiple transactions involving company stock and Restricted Stock Units (RSUs).
  • On November 28, 2025, Chalke acquired 2,500 shares of common stock through the Accuray Employee Stock Purchase Plan.
  • On November 28, 2025, Chalke was granted 110,000 Restricted Stock Units (RSUs). These RSUs vest over three years: 34% on the first anniversary, 33% on the second, and 33% on the third anniversary of the vesting commencement date.
  • On November 29, 2025, 50,314 previously granted RSUs were exercised, converting into 50,314 shares of common stock.
  • On December 1, 2025, 64,477 shares of common stock were disposed of at a price of $1.02 per share to satisfy tax withholding obligations in connection with the net settlement of RSUs.
  • Following these transactions, Chalke beneficially owns 459,806 shares of common stock and 100,629 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. While there's a disposition for tax, it's a standard practice and is offset by a significant RSU grant and ESPP acquisition, indicating continued executive alignment and participation in company equity.

Positives

  • Grant of 110,000 Restricted Stock Units (RSUs) aligns management's interests with long-term shareholder value through a multi-year vesting schedule.
  • Acquisition of 2,500 shares through the Employee Stock Purchase Plan indicates continued confidence in the company.

Negatives

  • Disposition of 64,477 shares of common stock for tax withholding purposes, reducing direct common stock ownership.

Future Outlook

The filing details the vesting schedule for the newly granted Restricted Stock Units, with 34% vesting on the first anniversary, 33% on the second, and 33% on the third anniversary of the commencement date, indicating future share releases.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide broader industry context. It reflects standard executive compensation practices within publicly traded companies, often involving equity grants like RSUs to incentivize long-term performance.

Comparison to Industry Standards

  • The RSU grant and subsequent tax-related disposition are standard practices for executive compensation in the medical technology industry, similar to peers like Varian Medical Systems (now Siemens Healthineers) or Elekta AB, where equity incentives are used to align executive interests with shareholder returns.
  • The vesting schedule of 34%/33%/33% over three years is a common structure designed to promote retention and long-term performance.

Stakeholder Impact

  • Shareholders: Increased alignment of executive interests with long-term shareholder value through RSU grants.
  • Employees: The ESPP participation indicates a benefit available to employees.

Next Steps

  • Future vesting of 110,000 RSUs on the first, second, and third anniversaries of the commencement date.
  • Potential future dispositions of shares upon vesting of RSUs to cover tax obligations.

Key Dates

DateDescription
11/28/2025Acquisition of 2,500 common shares via ESPP and grant of 110,000 Restricted Stock Units (RSUs).
11/29/2025Exercise of 50,314 Restricted Stock Units (RSUs) into common stock.
12/01/2025Disposition of 64,477 common shares for tax withholding related to RSU net settlement.
12/02/2025Date of filing signature.

Recommendation

hold

This Form 4 filing primarily details routine insider transactions, including an RSU grant and tax-related share dispositions. It does not contain information that would fundamentally alter the investment thesis for Accuray Inc. The RSU grant aligns executive incentives with long-term performance, which is a positive, but the overall impact on the company's valuation or operational outlook is minimal. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider transactions.

Keywords

Accuray, ARAY, Sandeep Chalke, Form 4, Insider Trading, Restricted Stock Units, RSU, Common Stock, Employee Stock Purchase Plan, ESPP, Executive Compensation, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.